<DOC>
	<DOCNO>NCT00003753</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , floxuridine , dexamethasone , irinotecan , use different way stop tumor cell divide stop grow die . Hepatic arterial infusion use catheter deliver chemotherapy directly liver . Combining one drug give different way may kill tumor cell remain surgery . PURPOSE : Phase II trial study effectiveness irinotecan combine hepatic arterial infusion floxuridine dexamethasone surgery treat patient liver metastasis colorectal cancer .</brief_summary>
	<brief_title>Floxuridine , Dexamethasone , Irinotecan After Surgery Treating Patients With Liver Metastases From Colorectal Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose ( MTD ) hepatic arterial infusion floxuridine ( FUDR ) dexamethasone give via implanted pump combination weekly intravenous irinotecan adjuvant treatment resection hepatic metastasis patient hepatic metastasis colorectal cancer . ( The MTDs irinotecan floxuridine reach 10/15/03 ; phase I close accrual 10/15/03 . ) - Determine efficacy combination chemotherapy liver resection , term 2-year survival 2-year recurrence rate , patient . - Determine pharmacokinetic effect intrahepatic FUDR liver resection metabolism irinotecan active metabolite , SN-38 patient . - Determine safety efficacy pump use deliver intra-arterial chemotherapy liver patient . OUTLINE : This dose-escalation* study floxuridine irinotecan . Patients undergo hepatic resection pump placement abdomen . About 4 week surgery , patient receive irinotecan IV 30 minute day 1 15 . Patients also receive floxuridine dexamethasone intra-arterially via implanted pump continuously day 1-14 . Treatment repeat every 28 day 6 course absence unacceptable toxicity disease progression . Sequential dose escalation irinotecan follow sequential dose escalation floxuridine . Cohorts 3-6 patient receive escalate dos irinotecan floxuridine maximum tolerate dos ( MTDs ) determine . The MTD* ( phase II dose ) define dose precede 2 6 patient experience dose-limiting toxicity . NOTE : *The MTDs irinotecan floxuridine reach 10/15/03 ; phase I close accrual 10/15/03 Patients follow every 3 month 2 year , every 4 month 2-4 year , every 6 month thereafter . PROJECTED ACCRUAL : A total 2-24 patient accrued phase I portion study within 1 year ( phase I close accrual 10/15/03 ) . A total 50 additional patient accrue study phase II dose level .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Floxuridine</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm colorectal adenocarcinoma Primary colorectal tumor must previously resect Potentially completely resectable hepatic metastasis ( removable cryoresection ) without current evidence metastatic disease No extrahepatic site disease No ascites hepatic encephalopathy PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 60100 % Life expectancy : Not specify Hematopoietic : WBC least 3,000/mm^3 Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hepatic : Bilirubin great 1.5 mg/dL Renal : Not specify Other : Not pregnant nursing No active infection PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : At least 4 week since prior chemotherapy Endocrine therapy : Not specify Radiotherapy : No prior radiotherapy liver At least 4 week since prior radiotherapy pelvis Surgery : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>stage IV colon cancer</keyword>
	<keyword>stage IV rectal cancer</keyword>
	<keyword>adenocarcinoma colon</keyword>
	<keyword>adenocarcinoma rectum</keyword>
	<keyword>liver metastasis</keyword>
	<keyword>recurrent colon cancer</keyword>
	<keyword>recurrent rectal cancer</keyword>
</DOC>